• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform

    9/22/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email

    MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution, empowering clinicians with the insights needed to make confident care decisions with ease. Heartflow also announced that Heartflow Plaque Analysis will be covered by Cigna across all of its lines of business, including Commercial and Medicare Advantage plans, beginning in October.

    Advanced Heartflow Plaque Analysis Platform Provides Clarity in 3D

    Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque quantification tool with a reported 95% agreement with the gold standard, IVUS, using blinded core lab adjudication.1 The latest algorithm advancement shows 21% improvement in plaque detection compared to the first-generation algorithm, so clinicians can be confident in their diagnosis and management of CAD.2

    "Understanding not only how much plaque is present, but also plaque type and distribution, is critical in predicting patient risk and guiding personalized treatment," said Matthew Budoff, M.D., Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles (UCLA) Medical Center. "With these enhanced capabilities, Heartflow Plaque Analysis provides clinicians with the clarity we need to move from detection to decision with speed and confidence."

    Leveraging enhanced AI, this new Plaque Analysis update marks the most sophisticated iteration of Heartflow's technology. It provides clinicians with an intuitive visual representation of plaque types, enabling rapid assessment of CAD location and severity. Heartflow's enhanced nomogram is powered by data from ~273,000 patients—a dataset 9x larger than any current plaque quantification study.3

    Cigna Adds Nationwide Coverage for Heartflow Plaque Analysis

    Cigna is the second national insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines issued by radiology benefit manager EviCore, following a similar decision by UnitedHealthcare. The updated coverage will become effective on October 1, 2025 for Cigna patients with acute or stable chest pain and mild-to-moderate narrowing of coronary arteries (1-69% stenosis) identified on coronary CTA.

    "Heartflow is proud to lead the way in coronary plaque analysis with our Next Gen platform, delivering the most representative visualization and context available for assessing patients' disease and risk. Cigna's decision to cover Heartflow Plaque Analysis is a testament to the power of our technology to positively impact care for its members across the United States," said John Farquhar, President and CEO of Heartflow. "Heartflow Analyses give clinicians a view of coronary plaque by type and impact on blood flow with FFRCT that's key to informing management strategies. These latest advancements build on Heartflow's record of proven innovation, leveraging clinical rigor and the world's largest dataset of coronary CTA images to continually improve our technology for clinicians and patients."

    Heartflow's continued advancement of plaque analysis technology follows the company's recent unveiling of the landmark DECIDE Registry data, which showed Heartflow Plaque Analysis led to medical management change in over 50% of patients beyond coronary CTA alone, resulting in an expected ~15% event reduction.4,5 Heartflow is dedicated to reshaping cardiovascular care and ensuring that physicians and patients have access to comprehensive, accurate, and efficient solutions for precision coronary care.

    About Heartflow, Inc.

    Heartflow is transforming coronary artery disease from the world's leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinicians with actionable insights into plaque volume and composition and its impact on blood flow – without the need for invasive procedures. Supported by ACC/AHA guidelines and more than 600 peer-reviewed publications, Heartflow has helped clinicians manage nearly 500,000 patients worldwide. Discover how we're shaping the future of cardiovascular care at heartflow.com.

    1 Ihdayhid A, et al. Radiol Cardiothorac Imaging. 2024. doi: 10.1148/ryct.230312 and internal bridging study with ICC correlation between first generation and second generation Plaque Analysis algorithm.

    2 U.S. Food and Drug Administration. 510(k) Premarket Notification: K250902. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250902.pdf

    3 Tzimas, et al., Presentation SCCT July 2025.

    4 DECIDE Registry. Rinehart, et al., Presented at SCCT July 2025.

    5 Collins et al. Lancet 2016. DOI: 10.1016/S0140-6736(16)31357-5

    Media Contact

    Elliot Levy

    [email protected]

    Investor Contact

    Nick Laudico

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5f268838-f806-4612-995b-af3aa4676cc0



    Primary Logo

    Get the next $HTFL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL

    DatePrice TargetRatingAnalyst
    9/2/2025$36.00Overweight
    Analyst
    9/2/2025$38.00Overweight
    Piper Sandler
    9/2/2025$35.00Buy
    Stifel
    9/2/2025$35.00Buy
    Canaccord Genuity
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Healthcor Partners Management Lp converted options into 6,697,556 shares (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    8/22/25 5:15:59 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Healthcor Partners Management Lp

    3 - Heartflow, Inc. (0001464521) (Issuer)

    8/22/25 5:13:10 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Large owner Bain Capital Life Sciences Investors, Llc converted options into 12,448,158 shares (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    8/13/25 4:00:11 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Heartflow with a new price target

    Piper Sandler initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    9/2/25 8:37:45 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Heartflow with a new price target

    Stifel initiated coverage of Heartflow with a rating of Buy and set a new price target of $35.00

    9/2/25 8:37:35 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

    -- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth. -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care. Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than

    10/8/25 8:00:00 AM ET
    $HTFL
    $INSP
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Nursing Services

    Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform

    MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution, empowering clinicians with the insights needed to make confident care decisions with ease. Heartflow also announced that Heartflow Plaque Analysis will be covered by Cigna across all of its lines of bu

    9/22/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

    MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET. A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com. About Heartflow, Inc.Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosab

    8/27/25 4:24:48 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    SEC Filings

    View All

    SEC Form 10-Q filed by Heartflow Inc.

    10-Q - Heartflow, Inc. (0001464521) (Filer)

    9/19/25 8:31:10 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Heartflow, Inc. (0001464521) (Filer)

    9/10/25 7:30:20 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Heartflow, Inc. (0001464521) (Filer)

    8/25/25 4:03:57 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care